Jan Wald Quotations

The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.

One thing the company loses by not being part of J&J is not having more money for market development education and training

My sense is J&J is going to have to acquire to get a growth rate that investors will think is respectable.

I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.

But that is an awfully long time to look out for pharmaceuticals.

I have a feeling that Temecula is pretty safe.

I don't think it's a sure thing by any stretch, but I think they have a good chance of making it.

I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.

It appears that a good portion of doctors are willing to give Guidant a fresh look in their practices, and perhaps faster than most believed.

I think it's an amazing turn of events.

I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.

I think they easily could go up to $76 without a lot of damage.

It is another indication that the processes could have been better ? but the company is working hard on it already.

I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.

J&J needs something like Guidant to revitalize its growth. People are now thinking that if J&J does walk away, St. Jude is in their scopes.

J&J needs something like Guidant to revitalize its growth,

People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.

The problem that Johnson & Johnson and any company even half the size of Johnson & Johnson faces is buying something that can impact their growth rate, and that's not an easy task.

What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.

Boston Scientific will do everything in its power to reach a deal with Guidant.

After all the noise they made, there would certainly be a lot of questions asked (if they raised their bid).

They might have passed the acid test of being too big.

There was nothing in the earnings report that would renew investor interest.

There's a lot of frustration among institutional shareholders and employees who own the stock.

It's less serious than I thought it was.

It's still a possibility. But the valuation is high, and one thing we learnt from the J&J bid for Guidant is they are very sensitive to valuation.

It's still a possibility. But the valuation is high, and one thing we learned from the J&J bid for Guidant is they are very sensitive to valuation.

It underscores why they were so bent on doing the Guidant deal.

They were being nickel-and-dimed by J&J. They had to get out of that loop.

In investors' minds, they've been accused of being a one-trick pony, and they don't have a pipeline. If they get Guidant, they answer both those questions. They'll be in one of the fastest-growing medical devices markets, for implantable defibrillators, and they'll have Guidant's pipeline.

If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.

Integration is going full-speed ahead. I don't think they would be concerned by a two-week delay in closing the deal, even though there's an interest payment.

I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.

If the relationship has been adversarial, the FDA, we believe, would not be as accommodating, even in speech.

I think of all the pieces, it's pharmaceuticals that are hurting them the most.

I certainly think it could be a stand-alone company. I'm not certain it should be.

I don't think there's much risk to employees ? especially the Minnesota contingent.

This is one of those times when actions speak louder than words.

The end of the fourth quarter looked better than the beginning, and 2006 is looking OK.

The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,

The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.